Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100S9UJ
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥443.9bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥228.6bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥66.5bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥36.8bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥66.4bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥36.6bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥50.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥27.5bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥1.75Tat 2023-09-30Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.66Tat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.4bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.26Tat 2023-09-30Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.26Tat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥187.3bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥53.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥36.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥30.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥67.272023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥36.992023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥67.242023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥36.972023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio72.1%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥119m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥84.1bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥10.6bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥265.7bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥57.6bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-09-30¥94.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-09-30¥8.3bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥443.8bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥76.6bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 690
ItemContextValueUnit
Non recurring profit or loss IFRSPrior1YTDDuration-4934000000JPY
Operating profit loss IFRSPrior1YTDDuration55977000000JPY
Finance income IFRSPrior1YTDDuration929000000JPY
Finance costs IFRSPrior1YTDDuration1978000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-303000000JPY
Profit loss before tax IFRSPrior1YTDDuration54624000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember265700000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember93956000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember84097000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember443754000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember119000000JPY
Revenue from external customers IFRSCurrentYTDDuration443874000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember57641000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember8317000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember10649000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember76608000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-1014000000JPY
Segment profit loss IFRSCurrentYTDDuration75594000000JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember-4641000000JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember－JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember-5191000000JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration_ReportableSegmentsMember-9833000000JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration_ReconcilingItemsMember145000000JPY
Amortization of intangible assets acquired through business combinations IFRSCurrentYTDDuration-9687000000JPY
Non recurring profit or loss IFRSCurrentYTDDuration585000000JPY
Operating profit loss IFRSCurrentYTDDuration66492000000JPY
Finance income IFRSCurrentYTDDuration1324000000JPY
Finance costs IFRSCurrentYTDDuration1489000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration100000000JPY
Profit loss before tax IFRSCurrentYTDDuration66428000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第109期第２四半期(自　2023年７月１日　至　2023年９月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)テルモ株式会社
Company name in english cover pageFilingDateInstantTERUMO CORPORATION
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO　佐藤　慎次郎
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03(3374)8111(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstantText · Plus
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都新宿区西新宿三丁目20番２号 東京オペラシティタワー 49F
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03(6742)8500(代表)
Name of contact person nearest place of contact cover pageFilingDateInstantText · Plus
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE01630
Fund codeFilingDateInstant－
Security codeFilingDateInstant45430
Filer name in japaneseFilingDateInstant
Original text (Japanese)テルモ株式会社
Filer name in englishFilingDateInstantTERUMO CORPORATION

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass